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The Peroxisome Proliferator-Activated Receptors (PPARs) PPARA and PPARD are regulators of lipid metabolism with important
roles in energy release through lipid breakdown, while PPARG plays a key role in lipid storage and adipogenesis. The aim of this
review is to describe the role of PPARs in lipid metabolism, adipogenesis, and obesity and evaluate the zebrafish as an emerging
vertebratemodel to study the function of PPARs. Zebrafish are an appropriatemodel to study human diseases, including obesity and
related metabolic diseases, as pathways important for adipogenesis and lipid metabolism which are conserved between mammals
and fish. This review synthesizes knowledge on the role of PPARs in zebrafish and focuses on the putative function of PPARs in
zebrafish adipogenesis. Using in silico analysis, we confirm the presence of five PPARs (pparaa, pparab, pparda, ppardb, and pparg)
in the zebrafish genomewith 67–74% identity to human andmouse PPARs.During development, pparda/b paralogs and pparg show
mRNA expression around the swim bladder and pancreas, the region where adipocytes first develop, whereas pparg is detectable in
adipocytes at 15 days post fertilization (dpf).This review indicates that the zebrafish is a promising model to investigate the specific
functions of PPARs in adipogenesis and obesity.
1. Introduction
In the last 30 years, obesity has become a worldwide epi-
demic, and according to the World Health Organization
(WHO), over 700 million people can be characterized as
obese [1]. Obesity is a risk factor for developing type II
diabetes mellitus, cardiovascular diseases and hypertension,
as well as cancer. Over the last decade, many studies have
described the important biological functions of Peroxisome
Proliferator-Activated Receptors (PPARs) and their role in
obesity. Genetic variation in PPARs results in altered fat
deposition and body weight, as studies on the develop-
ment of obesity, T2DM, dyslipidemia, and cardiovascular
diseases have identified single nucleotide polymorphisms
(SNPs) in PPAR genes [2]. PPARs are important factors for
adipocyte differentiation and energy homeostasis and are
highly expressed in tissue with active lipid metabolism. In
addition, PPARs are involved in embryonic development, cell
differentiation, and inflammation [3–5].
The aimof this review is to describe the function of PPARs
in lipid metabolism and adipogenesis, in particular their role
in obesity and related disorders. As numerous animal models
have been used to study the origin of obesity and to gain
better knowledge of PPAR-related molecular mechanisms,
we evaluate the zebrafish as an emerging model to study
adipogenesis. We hypothesize that PPARs in zebrafish have
similar functions as in mammals.
(1) Peroxisome Proliferator-Activated Receptors. PPARs are
nuclear hormone receptors which belong to the NR1C sub-
family of steroid receptor superfamily. The classifications
of PPARs in the nuclear receptor family are described
in a nomenclature system according to Nuclear Recep-
tors Nomenclature Committee [6]. Three PPARs have been
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identified in vertebrates, namely, PPARA (hPPAR, PPAR𝛼,
and NR1C1), PPARD (NR1C2, PPAR𝛽/𝛿, FAAR, NUCI, and
NUCII), and PPARG (NR1C3, PPAR𝛾) which are encoded
by different genes [4]. The zebrafish orthologs of PPARA,
PPARD, and PPARG are referred to as Pparaa, Pparab,
Pparda, Ppardb, and Pparg according to the ZFIN nomen-
clature (http://zfin.org/).
Like other nuclear receptors, PPARs have a protein
structure that generally consists of four parts, namely, an N-
terminal domain (NTD), a DNA-binding domain (DBD), a
ligand binding domain (LBD), and a connective structure
(hinge) [7, 8]. The NTD contains a ligand-independent
activation factor-1 (AF-1). The DBD consists of two zinc
fingers that specifically bind to the peroxisome proliferator
response element (PPRE) in the promotor regions of PPAR
target genes [9]. The C-terminal part of the protein, the
LBD, consists of 13 𝛼-helices and 4 𝛽-sheets which form
the ligand binding pocket. The LBD contains the ligand
dependent activation factor-2 (AF-2), and ligand binding to
AF-2 results in activation of the LBD [3, 10]. Expression
of PPARs is predominantly in the nucleus, though PPARA
and PPARG are also found in lower concentrations in the
cytoplasm as well [11, 12]. PPARs can be shuttled between the
cytoplasm and the nucleus by export receptors that recognize
two different nuclear localization signals (NLSs) on the PPAR
protein [12].
PPARs regulate transcriptional gene activation through
heterodimerization with retinoid X receptors (RXR) [13, 14].
All PPARs can form a complex with RXR, and heterodimer-
ization between PPAR and RXR is ligand independent [15,
16]. In the absence of ligands, PPAR:RXR heterodimers
bound to PPREs will act as a transcriptional repressor due
to binding of corepressor proteins such as nuclear receptor
corepressor 1 (NCoR) and silencing mediator of retinoic
acid and thyroid hormone receptor (SMRT). Binding of
a specific PPAR agonist to LBD leads to the release of
corepressor complex and recruitment of the coactivation
factors. Coactivators of PPARs include the steroid receptor
coactivator-1 (SRC-1), CREB-binding protein (CBP), PPAR-
binding protein (PBP), P300, cyclin G2, PPAR-interacting
protein (PRIP), and PPAR𝛾 coactivator-1 (PGC-1) [17–19].
As a consequence of a conformational change of the LBD,
the PPAR:RXR heterodimer binds to the PPRE present
in promoter regions in order to regulate transcription of
target genes by facilitating RNA polymerase II function.
The PPRE consists of direct repeats (DRs) containing two
hexanucleotide sequences AGGTCA which are separated
by one nucleotide [20]. The 5󸀠 flanking site of the PPRE
is important for PPAR isoform:RXR heterodimer binding
specificity and consists of a 7-nucleotide sequence consensus
(C[A/G][A/G]A[A/T]CT) [21].
The LBDof the PPARs is activated by specific endogenous
agonists such as fatty acids, fatty acids derivatives, phos-
pholipids, eicosanoids, and prostaglandins (Table 1). Many
synthetic ligands of PPARS have been developed for the
treatment of diabetes mellitus and high levels of triglycerides
and cholesterol, such as the thiazolidine drugs (TZDs) and
fibrates (Table 1). Recently, chemicals present in the environ-
ment throughhuman activity such as pesticides and phthalate
ester plasticizers have also been identified as PPAR ligands
[22, 23].
(2) Biological Function of PPARs in Lipid Metabolism and
Adipocyte Differentiation. PPARA is mainly involved in
fatty acid oxidation and is highly expressed in tissue with
mitochondrial and peroxisomal 𝛽-oxidation such as brown
adipose tissue (BAT), liver, and to a lower extent also in heart,
kidney, and muscles [24]. PPARA is activated by long chain
unsaturated fatty acids, eicosanoids, and synthetic fibrates,
which have been developed to treat dyslipidemia by reducing
triglyceride levels [25, 26].
PPARD is ubiquitously expressed and has a common
function in fatty acid metabolism comparable to PPARA.
PPARD also seems to be involved in embryo implantation,
keratinocyte differentiation, and wound healing [27, 28].
PPARD is a promising drug target for heart defects caused
by diabetes. A recent study has shown that PPARD induces
glucose transport to the heart muscle cells and that diabetes
patients have decreased PPARD expression in cardiac muscle
when glycemic levels are high [29]. Synthetic agonists for
PPARD have been developed for the treatment of obesity and
related conditions, as overexpression increases glucose influx,
reduces damage, improves insulin sensitivity, and reduces
lipid accumulation [30].
In humans and mice, the PPARG gene has three splice
variants: PPARG1, PPARG2, and PPARG3. PPARG1 and
PPARG3 translate into identical proteins whereas PPARG2
contains an extra 28 amino acid regions in the NTD due
to alternative splicing [31]. PPARG2 is an essential regulator
of adipocyte differentiation and lipid storage in WAT, while
PPARG1/3 has a more general function in lipid metabolism
and is expressed in the colon andmacrophages [32, 33].Many
synthetic agonists have also been designed for PPARG2, with
the most well known being the TZDs and fibrates, both used
for the treatment of metabolic disorders like type 2 diabetes
mellitus (T2DM). TZDs that target PPARG are used to
increase insulin sensitivity and reduce glycemia in the treat-
ment of diabetes, and, additionally, PPARG activation has
shown protective effects on the vasculature [34]. Activation
of PPARG by TZDs has also been linked to increased weight
gain in patients based on PPARG function in adipocyte
differentiation and its involvement in lipid homeostasis [35].
As PPARG has also been shown to regulate certain processes
in cancer development, it might be a possible additional
target in the treatment of cancer. New generation drugs that
target both PPARA and PPARG are very promising and have
already been used in treatment, as they show hypolipidemic,
hypotensive, anti-inflammatory, and antiatherogenic action
[29, 36, 37].
2. Zebrafish as Model for Obesity
Numerous animal models have been used to study the
etiology of obesity in order to gain better understanding of
molecular mechanisms and possible treatments. In the last
decade, zebrafish (Danio rerio), shown in adult and larval
stages in Figure 1, have emerged as an excellent model to
study human diseases [38] due to a number of advantages
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Table 1: Endogenous and synthetic ligands of vertebrate PPARs.
PPAR Ligand type Potential agonists
PPARA
Endogenous
Fatty acids (lauric acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid (Xenopus),
docosahexaenoic acid (Xenopus), petroselinic acid (Xenopus), oleic acid (Xenopus), and elaidic acid
(Xenopus)) [66, 67]
Eicosanoids (fatty acid-derived) (e.g., leukotriene B
4
) [68, 69]
Prostaglandin J2 (fatty acid-derived) [70]
Endocannabinoids [71]
Synthetic
Nonsteroidal anti-inflammatory drugs (NSAIDs) [72]
Fibrates (e.g., gemfibrozil, Bezafibrate, clofibrate, fenofibrate, ciprofibrate, pirinixic acid (Wy 14643), and
GW2331) [3, 67, 73, 74]
ETYA (5,8,11,14-eicosatetraynoic acid) (Xenopus) [66]
PPARD
Endogenous Fatty acids (e.g., docosahexaenoic acid, linoleic acid) [69]Very Low Density Lipoproteins (VLDL) components [75]
Synthetic Fibrates (Wy-14,643, Bezafibrate) [69]GW501516, GW800644 [76, 77]
PPARG
Endogenous Fatty acids (docosahexaenoic acid, linoleic acid (mouse)) [14, 69]Prostaglandin J2 metabolite 15-deoxy-delta 12,14-PGJ2 [70, 78]
Synthetic
NSAIDs [72]
Thiazolidinediones [79]
ETYA (5,8,11,14-eicosatetraynoic acid) (mouse) [14]
Prostaglandin J2 derivatives [70, 78]
Fibrates (Bezafibrate, clofibrate, and GW2331) [14, 67]
of this system. Zebrafish develop rapidly and have a short
life cycle and detailed genome sequence information is
available. The availability of new genome editing techniques
like TALENs [39] and CRISPR-Cas9 [40], as well as several
transgenesis tools (MultiSiteGateway Tol2, BAC transgenesis,
Gal4/UAS, and Q system), enables the study of the function
of genes. Zebrafish can also be used for high-throughput
forward genetic and chemical screens [41–43], facilitating the
identification of molecules that regulate biological functions.
Zebrafish are a promising model for obesity research, as
lipid metabolism pathways are conserved between mammals
and fish [44–46]. Zebrafish have the key organs that are
important for energy homeostasis and metabolism in mam-
mals, aswell as other key functions such as appetite regulation
in the brain [47], insulin regulation [48], endocrine signaling
through leptin [49], and lipid storage in white adipocytes [50,
51]. Like humans, zebrafish kept on a high caloric diet show
increased plasma triglyceride levels and hepatic steatosis as
well as comparable expression patterns of genes involved in
lipid metabolism such as LEP, SREBP, PPARA, PPARG, and
NR3H1 [45]. It has also been shown that obesity in zebrafish
coincides with an increased plasma fibrinogen concentration
that is induced via IL-6 and IL-1Bl secreted from visceral
white adipose tissue. Zebrafish, as well as mice, rats, and
humans, also produce a higher amount of IL-6 and IL-1B
upon high caloric feeding, adding to the evidence that major
metabolic pathways between fish and mammals are very
similar [45]. It is important to note, however, that zebrafish
may not be an appropriate model for studying thermogenesis
in higher vertebrates since brown adipose tissue has not
been identified in poikilothermic animals. Zebrafish appear
to not make thermogenic brown adipocytes, relying instead
on thyroid hormone-mediated processes to generate heat in
their muscles [52]. Although uncoupling proteins (UCPs 1–
5) have been identified in zebrafish that are expressed in
brain, liver, and muscle tissue but not in adipose tissue [53],
differences in thermogenesis between mammals and fish are
important to consider.
One major advantage of the zebrafish as a model of
obesity is its optical transparence which allows temporal
monitoring of adipocyte formation and fatty acid uptake in
vivo [54]; adipocytes can be visualized in developing larvae
with various dyes, including the sudanophilic dye Oil Red
O (ORO) or Sudan dyes (Sudan III, Sudan IV, and Sudan
Black B) and fluorescent dyes like Nile Red or LipidGreen
(Figure 1(c)) [50, 55]. ORO and Sudan dyes are lipophilic
(fat-soluble) dyes that can be applied as a soluble colorant
for neutral lipids and cholesteryl esters. Nile Red binds to
both neutral lipids and phospholipids while LipidGreen only
binds to neutral lipids [55, 56]. Dyes such as Sudan Black
B and ORO are fixative based dyes, and fixation techniques
are time consuming and may also cause deformation of lipid
droplets in tissue [57], while Nile Red and LipidGreen can
be applied in vivo. The potential of using Nile Red staining
in zebrafish larvae as a whole-organism test for screening
pharmaceuticals and toxicological agents has recently been
demonstrated [58].
3. Adipogenesis and Lipid
Metabolism in Zebrafish
Adipose tissue develops from pluripotent mesenchymal stem
cells (MSCs) and commitment to this cell lineage gives
rise to preadipocytes (determination phase) and subsequent
terminal differentiation adipocytes (differentiation phase)
(Figure 1(d)) [59, 60]. In the transcriptional cascade leading
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Figure 1: (a) An adult female and male zebrafish. (b) Developing zebrafish larvae (15 dpf). (c + c󸀠) A transmission light image of adipocytes
in developing larvae (15 dpf) (left) and a fluorescent image after staining lipids with LipidGreen (right). (d) Transcriptional network of factors
important for adipocyte differentiation in zebrafish and mammals.
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Table 2: Location and characteristics of the PPAR genes in zebrafish genome (GRCz10, Havana, and NCBI).
PPAR Gene Chromosome location GRCz10 NCBI Nucleotide cds (bp) Protein (aa) Exons
pparaa ENDARG00000031777 4; rev CM002888.1 NM 001161333 1,413 470 6
pparab ENDARG00000054323 25; forw CM002909.1 NM 001102567 1,380 459 7
pparda ENDARG00000044525 22; forw CM002906.1 XM 694808, XM005168286 1491 496 7
ppardb ENDARG00000009473 8; forw CM002892.1 NM 131468 1554 517 7
pparg ENDARG00000031848 11; rev CM002895.1 NM 131467 1584 527 7
to the differentiation of WAT (Figure 1(d)), the nuclear
hormone receptor PPARG and CCAAT/enhancer-binding
protein (C/EBP𝛼) are key players. Two other members of
the C/EBP family, C/EBP𝛽 and C/EBP𝛿, are also important
factors during differentiation into adipocytes [59, 61, 62].
C/EBP𝛼 is a transcription factor that regulates PPARG
expression but also autoregulates its own expression. In
zebrafish, orthologs of these genes are expressed in adipocytes
and liver [51].The terminal differentiationmarkers like leptin
and fabp11a are also expressed. Adiponectin has also been
found in adult zebrafish adipose tissue [63].
During the first 4-5 days of development, zebrafish
embryos are dependent on nutrients provided by the yolk sac
which contains essential fat-soluble vitamins and triacylglyc-
erol (TAG), as well as cholesterol. At days 5-6, the yolk sac
is depleted and it is essential that larvae are provided with
food to start to eat. The first signs of adipogenesis become
visible at 8 days post fertilization (dpf) in the visceral cavity
close to the pancreas but only in the minority of larvae. In
most larvae, the first adipocytes translocate asymmetrically
to the right visceral cavity [50]. Most adipocytes are observed
from 12 dpf onwards (standard length (SL) of > 5mm) in
the pancreatic area [51]. In our laboratory, using LipidGreen
staining, adipocytes are clearly visible at 15 dpf in the visceral
region in a subset of larvae (Figure 1(c)). The amount of
adipocytes is correlatedwith size of the larvae rather than age,
suggesting body-length dependent lipid storage in adipocytes
[50, 51]. At 17 dpf, all larvae have WAT in the pancreatic and
visceral area, indicating that visceral WAT development is
not dependent on size but regulated by age. Subcutaneous
(20 dpf, SL > 8,2mm) and cranial (22 dpf, SL > 9,4mm)
adipocytes develop in a size-dependent manner [51]. Adult
fish have the largest adipocyte deposits in the visceral regions,
but smaller deposits are found subcutaneously in the tail
and jaw, and in the periorbital regions. Zebrafish adipocytes
are metabolically active and are able to communicate via
gap junctions [64]. The adipocyte lipid droplet size can vary
between 1 and 100 𝜇m and while most contain one large
droplet, some may contain multiple smaller droplets in the
early stage of development. These characteristics are con-
formant to mammalian adipocyte development and provide
evidence that zebrafish contain WAT similar to mammals
[50, 65].
4. PPARs in Zebrafish
The presence of five ppar genes in the zebrafish genome has
been described previously [80–82]. We performed an in silico
study to examine the homology of zebrafish PPARs with
orthologs in different species. Using the TBLASTX search
tool in Ensembl database (Ensembl GRCz10, http://www
.ensembl.org/Danio rerio/Info/Index), we checked for all
five ppar genes in the newest version of zebrafish genome
sequence available (GRC10). Based on the Havana/Ensembl
merged sequences and the mammalian/zebrafish protein
sequences, cDNA, and Nucleotide Database (NCBI), tran-
scripts could be identified (Table 2). The zebrafish genome
has undergone complete genome duplication in the teleost
lineage after the divergence of fish and mammal ancestors
[83, 84]. Because of this, zebrafish have two PPARA (pparaa,
pparab) and PPARD (pparda, ppardb) genes that are located
on separate chromosomes (ohnologs). Only one PPARG
(pparg) gene has been identified. pparaa is located on the
reverse strand of chromosome 4 while pparab is located at
forward strand of chromosome 25. The orthologs of PPARD
are located on chromosome 22 (pparda) and chromosome
8 (ppardb) and are both positioned on the forward strand.
In zebrafish, pparg gene is positioned on chromosome 11 on
the reverse strand (Table 2). Comparing genomic regions of
PPARs in human and zebrafish, we found conserved synteny
regions using The Synteny Database [85]. pparaa and pparab
showed both synteny to the same region at human Chr
22 and showed synteny between their location on zebrafish
genome. Also, pparda and ppardb have synteny to the same
location at human Chr 6, and as their PPARA orthologs.
pparda and ppardb showed synteny between their location
on zebrafish genome. The zebrafish genome surrounding
pparg is highly conserved compared to human Chr 3 (Sup-
plemental data 3A–C in Supplementary Material available
online at http://dx.doi.org/10.1155/2015/358029). The con-
served regions contain the same genes in both organisms,
which indicates a conserved functional relationship between
syntenic genes.
Pparaa and Pparab encode for proteins that are 470 and
459 amino acids (aa) long, respectively. Pparda consists of
496 aa, and Ppardb is 517 aa long. Pparg is the longest PPAR
in zebrafish and is 527 aa in size. Protein alignment and
the phylogenetic tree are based on 49 amino acid sequences
from 15 different species (Supplemental Data 1). The pro-
tein sequences were subjected to homology analyses using
PRALINE multiple sequence alignment (http://www.ibi.vu
.nl/programs/pralinewww/) (Supplemental Data 1 and Sup-
plemental Data 2). The phylogenetic tree was constructed
using the softwareGeneious 9.0 (BLOSUM62matrix, Genetic
Distancemodel: Jukes-Cantor; Biomatters, http://www.gene-
ious.com/) (Figure 2). All zebrafish PPARs show protein
identity to human and mice orthologs, with similarity of
human PPARA to zebrafish Pparab and Pparaa of 74% and
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Figure 2: Phylogenetic tree of the PPAR orthologs in various organisms based on amino acid sequence difference (BLOSUM62 matrix). The
phylogenetic tree is generated using the Geneious 9.0 software. Protein accession numbers information is provided in Supplemental Data 1.
67%, respectively. Zebrafish Pparda and Ppardb showed 71%
and 73% similarity to human PPARD. Besides that, zebrafish
Pparg is 67% similar to human PPARG (Table 3).
Amino acid sequence analysis of different homologues
revealed that PPARs consist of a highly conserved pro-
tein family. The phylogenetic tree shows also that PPARA,
PPARD, and PPARG proteins form distinct clusters of pro-
tein, although PPARA and PPARD were clustered together
and the PPARG branch stands alone. The first gene duplica-
tion event of the PPARgene family probably occurred in bony
fish before being separated from birds and mammals. The
second gene duplication is vertebrate specific and resulted in
the different PPAR isotypes (A, D, and G) [86, 87]. After the
gene duplication events, the PPARs acquired ligand binding
capacities in an independent manner [88] and started to
evolve by mutations in each PPARS resulting in refined
specificity for ligands [87]. Zhao and colleagues [82] aligned
the sequences of the DBD and LBD between human and
11 different species. The DBD and LBD for all PPAR are
highly conserved between the different species, except for
the DBD and LDB in Xenopus PPARD which are far much
less conserved (83% and 75%, resp.). One explanation can
be that PPARD is less evolved in Xenopus compared to the
other species and therefore has a separated position in the
phylogenetic tree.
The zebrafish PPAR proteins contain several large regions
of amino acids that are highly conserved (Supplemental
Data 2). The N-terminal region of zebrafish PPARs is less
similar, as this region is highly variable between organisms.
The N-terminal region contains the conserved AF-1 that
can be activated by endogenous factors like hormones and
cytokines. In contrast, the AF-2 site located in the C-terminal
region remains well conserved. Like human PPARs, zebrafish
Pparaa, Pparab, and Pparg contain a threonine/serine-rich
NLS2 site that is involved in cytoplasm-nucleus shuttling
of the PPARs. This site was not found in Ppard ohnologs,
however, which have a threonine/serine-rich part earlier in
the protein which could possibly result in a similar action.
The overall conservation of PPARG is fairly high between
organisms, except for three fish species including the Japanese
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Table 3: Comparison of PPARs between human, mouse, and zebrafish.
PPAR Human Mouse Zebrafish
PPARA
Genes 1 1 2
Splice variants 1 1 1 per gene
Isoforms 1 1 1 per gene
Size (cds, bp) 1,407 1,407 pparaa: 1,413pparab: 1,380
Protein similarity to zebrafish 67% for pparaa74% for pparab
65% for pparaa
71% for pparab
PPARD
Genes 1 1 2
Splice variants 1 1 1 per gene
Isoforms 1 1 1 per gene
Size (cds, bp) 1,326 1,323 pparda: 1,491ppardb: 1,554
Protein similarity to zebrafish 71% for pparda73% for ppardb
70% for pparda
73% for ppardb
PPARG
Genes 1 1 1
Splice variants 4 1 1
Isoforms 2 2 1
Size (cds, bp) PPARG1 = 1,434PPARG2 = 1,518
PPARG1 = 1,428
PPARG2 = 1,518 pparg: 1,584
Protein similarity to zebrafish 67% 67%
medaka (Oryzias latipes), salmon (Salmo salar), and rainbow
trout (Oncorhynchus mykiss), which have several (up to 5)
additional amino acid regions throughout the protein. In all
fish species, the LDB of PPARG is less conserved to human
(74–78%) and this can be explained by the rapid evolutionary
rate of PPARG in teleosts [82]. When comparing human and
zebrafish PPARG, two major differences between zebrafish
Pparg and human PPARG were found. Firstly, the first 30
amino acids from the N-terminus differ highly between
zebrafish Pparg and both hPPARG isoforms. In this region
of the protein, hPPARG2 contains extra 28 amino acids
compared to the hPPARG1 isoform. Conversely, zebrafish
Pparg contains only 16 amino acids in this region that differ
in all except two amino acids from hPPARG2. Secondly,
zebrafish Pparg has an extra 27 amino acid regions starting
from the 156th amino acid. Other fish species also have extra
amino acid sequence so it is possible that, during evolution,
teleost fish gained additional coding sequences which can
have implications for protein folding and functionality. We
also observed that all fish species analysed have an extra
protein sequence in the ligand binding domain visible at
amino acid position 401 in the protein alignment. This extra
sequence is not a part of the ligand binding pocket and
presumably should not interfere with binding to specific
ligands. However, a previous study has shown differences
in ligand binding specificity, as sequence comparison of
zebrafish PPARg to human and mice PPARG revealed resid-
ual differences within the LDB [89].
The phylogenetic tree shows that the zebrafish PPARA
ohnologs have evolved further from each other compared
to the zebrafish PPARD ohnologs (Figure 2). The zebrafish
PPARDohnologs havemost likely retained the same function
(subfunctionalization), while the zebrafish PPARA ohnologs
might have been subject to neofunctionalization [80]. pparab
has more similarities with salmon and rainbow trout, while
pparaa is on a separate branch in the phylogenetic tree and
has a higher homology with Japanese medaka. Additionally,
zebrafish PPARA and PPARD ohnologs seem to be more
related to each other than to zebrafish PPARG.
In fish, PPARs have been identified and characterized
but not much is known about their expression during
developmental stages and adipogenesis. Zebrafish PPARs are
expressed during development and so far little is known
of the expression profiles of the paralogs pparaa, pparab,
pparda, and ppardb. The limited expression studies that have
been performed show that ppardb and pparg mRNA are
already expressed early in development (5–10 hours post
fertilization (hpf)) in whole embryo. From 20 hpf on, the
expression is more intensive in the head region and continues
to be specifically expressed in the head, branchial arches,
and pectoral fin at 36 hpf. From this time point, expression
data for pparda is also available and comparable to that
of ppardb and pparg. At 5 dpf, gene expression is detected
around the swim bladder (pparda, ppardb, and pparg), in the
liver (pparda, pparg), in the intestinal bulb (pparda), and also
in the complete intestinal tract (pparg) [80]. The expression
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patterns of ppard paralogs and pparg can be an indication
that they play a role in adipogenesis since it is known that
first adipocytes arise in the pancreatic region underneath
the swim bladder [50, 51]. During the larval stage (15 dpf),
pparg mRNA is localized in developing adipocytes within
the pancreas and the intestinal epithelium in the same cells
where Nile Red staining was observed [50]. Expression of the
pparg gene is specifically detected in visceral adipose tissue
and pancreas as opposed to liver [51].
5. Conclusions
PPARs are important factors in energy homeostasis and obe-
sity development. While PPARA and PPARD are necessary
for lipid breakdown, PPARG plays a role in lipid accumu-
lation and adipogenesis. Single nucleotide polymorphisms
in PPARs have been implicated in the development of obe-
sity, T2DM, lipodystrophy, dyslipidemias, and cardiovascular
risk. The zebrafish is an emerging model for research in obe-
sity and related metabolic diseases and could be very useful
for providing insight into the role of PPARs in the origins of
obesity. All five PPAR genes (pparaa, pparab, pparda, ppardb,
and pparg) showprotein similarity to human andmice PPARs
varying from 67 to 74%. Three of the five zebrafish PPARs
(pparda, ppardb, and pparg) show expression of mRNA in
regions around swim bladder and pancreas that correlate to
the sites where first adipocytes will develop, and at 15 dpf,
pparg expression is detected in developing adipocytes. This
colocalization suggests a role for PPARs in adipogenesis.
However, detailed expression studies of PPARs during early
stages of adipocyte development are not available, and to
determine the subcellular expression of the different PPARs
in zebrafish, specific antibody staining needs to be performed
or transgenic fish lines should be generated. In addition,more
conclusive evidence of the function of PPAR in zebrafish
adipogenesis can be obtained by the generation of mutant
lines. Taken together, this review shows that the zebrafish is
a promising model for elucidating the specific functions of
PPARs in adipogenesis and obesity.
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